WASHINGTON, D.C. (TheStreet) --The FDA advisory panel convening Thursday to assess MELA Sciences' (MELA) skin cancer detection device will be a disaster for the company and its dwindling number of shareholders.
The FDA panel's experts will vote against MELAFind because the FDA has already made it very clear that the noninvasive computerized imaging device, as studied, doesn't work and may actually harm patients.
I don't feel the need to hedge my prediction of a MELAFind rout tomorrow. I've read a lot of damning reviews of experimental drugs and medical devices conducted by FDA in my ten years covering the biotech beat, but I cannot remember any FDA review until MELAFind in which the agency states flatly that approval could hurt patients.
Yet that's what FDA concluded about MELAFind in a review of the device released Tuesday. The FDA's warning is alarming:"FDA's Mission is to Protect and Promote the Public Health and the FDA review team has significant concerns this device has not been studied adequately for its current indications for use and therefore puts the health of the public at risk," FDA concluded. MELA shares fell more than 50% Tuesday but were up 2% Wednesday to $3 as analysts who have long backed company tried to reassure investors that MELAFind still had a chance for a positive vote Thursday. More likely, MELA's stock price will soon fall farther and trade closer to the value of the company's dwindling cash, now a bit more than a $1 a share. I've been questioning MELAFind's accuracy for months but even I was surprised at the ferociousness by which FDA attacked MELA Science and the device. The FDA, in its review, accuses the company of reneging on an agreement to study the device in certain patients at risk for melanoma. The FDA concluded that data from a pivotal study showed MELAFind to be less accurate than trained dermatologists in detecting potentially deadly melanoma, raising the risk of misdiagnosis. And MELAFind's benefit was "clinically meaningless" because the device does not reduce the number of biopsies and in fact, may actually force doctors to perform more biopsies, FDA found.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV